Interview with the CEO: Dexcom, Inc. (NASDAQ:DXCM)
Terrance H. Gregg is CEO of Dexcom, Inc., first joining the Dexcom board of directors in 2005, and subsequently appointed President and CEO in 2007, and CEO in 2011. In 2002, he retired as President of Medtronic MiniMed, a world leader in diabetes management systems. He became President and Chief Operating Officer of MiniMed, Inc., in 1996 and was instrumental in Medtronic’s $3.4 billion acquisition of MiniMed in 2001. He also served in executive positions with Smith & Nephew and Allergan, Inc. Mr. Gregg served as the 2003 to 2004 Chair of the Research Foundation Board of the American Diabetes Association. In 2010, Mr. Gregg and his wife were recognized by the Juvenile Diabetes Research Foundation — JDRF — with one of its highest honors, the 2010 Angel Award. Most recently, Mr. Gregg was honored as one of the San Diego regional finalists for the Ernst & Young Entrepreneur of the Year Award 2011 and named by MassDevice.com as one of 28 chief executives, who exemplify cutting-edge leadership and innovative thinking in the medical device industry, to its inaugural CEO Class of 2011. Mr. Gregg currently serves on several advisory boards, including the Scripps Translational Science Institute. Mr. Gregg received a Bachelor of Science degree from Colorado State University in 1971. Profile
TWST: Could you provide a brief overview of the company and the products that it’s selling?
Mr. Gregg: Dexcom is a world leader in continuous glucose sensing technology. We